A novel way to characterize ADCs with unmatched throughput and high-quality data

Phenomenex Inc. has launched Biozen Native RP-1 and RP-5. As antibody-drug conjugates (ADCs) continue to emerge as a pivotal approach in targeted cancer therapeutics, the demand for precise and efficient characterization methods is increasing. These innovative chromatography columns are designed to transform ADC characterization through reversed-phase separation under native conditions, allowing online mass spectrometry (MS) detection.

The proprietary RP-1 and RP-5 particle technology and surface chemistry allow rapid and robust native reversed phase resolution of all drug to antibody ratio (DAR) species, including positional isomers while facilitating faster and more efficient analyses compared to traditional methods.

The newly designed particle allows for reduction in run times and sample manipulation, ensuring that laboratories can achieve higher quality data for ADCs using these advancements in chromatographic media and methods.

“Our team is excited by the advanced ADC characterization capabilities enabled by this new, first of its kind, native reversed phase chromatography product, Biozen Native RP,” says Carl Sanchez, principal scientist of Research and Development at Phenomenex. “This product provides more rapid access to advanced insights into ADC chemistry allowing faster lead identification and optimization.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>